Switch to:
More From Other Websites
CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase... Sep 22 2014
CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference Sep 19 2014
Federman & Sherwood Investigates CytRx Corporation for Possible Violations of Federal Securities... Sep 16 2014
Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities... Sep 15 2014
Zeldes & Haeggquist, LLP Continues Investigation of CytRx Corporation Sep 15 2014
CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as... Sep 09 2014
CytRx Updates Presentation Time at Aegis 2014 Healthcare & Technology Conference Sep 05 2014
CytRx to Present at Upcoming Investor Conferences in New York City and Las Vegas Sep 02 2014
CytRx is pouring money into R&D of cancer-fighting drugs Aug 31 2014
CYTRX CORP Financials Aug 19 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into CytRx... Aug 11 2014
Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma... Aug 07 2014
CYTRX CORP Files SEC form 10-Q, Quarterly Report Aug 06 2014
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2014
CytRx Reports 2014 Second Quarter Financial Results Aug 06 2014
Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities... Aug 05 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into CytRx... Jul 09 2014
CytRx Added to Russell 3000® and Russell 2000® Indexes Jun 30 2014
CYTRX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 27 2014
Five Analyst Stock Picks With 100% or More Implied Upside Jun 07 2014
Celldex: The Race Leader In Glioblastoma Multiforme May 29 2014
CytRx Issues Statement Regarding Recent Lawsuits Mar 27 2014
CytRx Initiates Pivotal Global Phase 3 Clinical Trial with Aldoxorubicin for Second-Line Treatment... Mar 24 2014
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against CYTRX CORPORATION... Mar 17 2014
CytRx Establishes Research and Development Team and Opens New Laboratory to Develop Albumin-Binding... Mar 17 2014
CytRx Reports 2013 Financial Results Mar 05 2014
CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of... Feb 05 2014
CytRx to Present at the 16th Annual BIO CEO & Investor Conference on February 10, 2014, in New York... Feb 03 2014
CytRx Announces Pricing of Approximately $75 Million Public Offering of Common Stock Jan 31 2014
CytRx Announces Proposed Public Offering of Common Stock Jan 30 2014
CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related... Jan 23 2014
CytRx Receives FDA Approval to Extend Aldoxorubicin Dosing Cycles until Disease Progression in... Jan 21 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development Jan 16 2014
CytRx Corporation Doses First Patient in Phase 2 Clinical Trial with Aldoxorubicin for the Treatment... Jan 14 2014
CytRx Reports Additional Analyses Supporting Highly Statistically Significant Positive Results from... Jan 08 2014
CytRx to Hold Conference Call December 11, 2013 at 10:30 a.m. Eastern Time to Discuss Results of... Dec 10 2013
CytRx Corporation to Present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday,... Dec 04 2013
CytRx to Present at the Sixth Annual LD MICRO “Main Event” Conference in Los Angeles on December... Nov 26 2013
CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin in Patients with Unresectable Glioblastoma... Nov 20 2013
CytRx Reports Further Positive Interim Data from Global Phase 2b Clinical Trial with Aldoxorubicin... Oct 31 2013


No Entry for this criteria! We are updating our databases daily, please come back later!

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK